Authors :
Khairunnisa Syahputra; Ervinawati Elyaswanto; Evita Tiara Maharani; Eko Yulianto; Siti Susanti; Sumariyah Sumariyah; Fadhilah Nur Fahada; K. Sofyan Firdausi; Muhammad Nur
Volume/Issue :
Volume 8 - 2023, Issue 11 - November
Google Scholar :
https://tinyurl.com/3xt7sshc
Scribd :
https://tinyurl.com/b39fpmk6
DOI :
https://doi.org/10.5281/zenodo.10243164
Abstract :
Major autohemotherapy is a medical ozone
therapy technique that is gaining increasing importance
in treating several diseases. Analysis of the production of
standard doses of medical ozone for antihyperuricemia
in major autohemotherapy using double dielectric
barrier discharge (DDBD) with a copper plate electrode
configuration has been carried out. The results of the
research show that the higher the applied voltage, the
greater the concentration obtained for the low flow rate
used. From the results above, the dose obtained is
between 11.8 μg to 50.7 μg, which is the dose for therapy
using the Major Autohrmotherapy method as
antihyperuricemia. This dose has been tried on rabbits
and the results of the treatment showed
antihyperuricemia
Keywords :
Medical Ozone, Double Dielectric Barrier Discharge, Major Autohemoteraphy (MAH), Hiperurisemia.
Major autohemotherapy is a medical ozone
therapy technique that is gaining increasing importance
in treating several diseases. Analysis of the production of
standard doses of medical ozone for antihyperuricemia
in major autohemotherapy using double dielectric
barrier discharge (DDBD) with a copper plate electrode
configuration has been carried out. The results of the
research show that the higher the applied voltage, the
greater the concentration obtained for the low flow rate
used. From the results above, the dose obtained is
between 11.8 μg to 50.7 μg, which is the dose for therapy
using the Major Autohrmotherapy method as
antihyperuricemia. This dose has been tried on rabbits
and the results of the treatment showed
antihyperuricemia
Keywords :
Medical Ozone, Double Dielectric Barrier Discharge, Major Autohemoteraphy (MAH), Hiperurisemia.
